Try our beta test site
24 studies found for:    Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting U.S. CTEPH Registry
Conditions: Chronic Thromboembolic Pulmonary Hypertension (CTEPH);   Pulmonary Hypertension
Intervention:
2 Recruiting Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
Conditions: Coronary Artery Disease;   Coronary Disease;   Myocardial Ischemia;   Heart Diseases;   Cardiovascular Diseases;   Arteriosclerosis;   Arterial Occlusive Diseases;   Vascular Diseases
Intervention: Procedure: CorPath-assisted Percutaneous Coronary Intervention
3 Recruiting Lumbar Drain vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage
Conditions: Vasospasm, Intracranial;   Subarachnoid Hemorrhage
Interventions: Device: Extraventricular Drain;   Device: Lumbar Drain
4 Recruiting PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
Condition: Portopulmonary Hypertension
Interventions: Drug: Macitentan;   Other: Placebo
5 Recruiting Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Condition: Abdominal Aortic Aneurysm (AAA)
Intervention: Device: Nellix System
6 Recruiting Evaluation of the Duration of Therapy for Thrombosis in Children
Condition: Venous Thrombosis
Interventions: Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention
7 Recruiting Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension
Conditions: Glaucoma, Open-Angle;   Ocular Hypertension
Interventions: Drug: Bimatoprost sustained-release;   Other: Sham;   Drug: Timolol;   Drug: Timolol Vehicle (placebo)
8 Recruiting The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Macitentan;   Drug: Tadalafil;   Drug: Selexipag
9 Recruiting A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ubenimex;   Other: placebo
10 Recruiting Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke
Condition: Stroke
Interventions: Device: Telerehabilitation Therapy;   Behavioral: In-Clinic Therapy
11 Recruiting Women's Heart Attack Research Program- Imaging Study
Condition: Myocardial Infarction
Interventions: Device: OCT;   Other: CMR
12 Recruiting Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Conditions: Non-Hodgkin Lymphoma;   Burkitt's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Waldenstrom Macroglobulinemia
Intervention: Drug: ADCT-402
13 Recruiting Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Conditions: Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
14 Recruiting Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
15 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Solid Neoplasm;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib
16 Recruiting Post Market Surveillance Study of the Wingspan Stent System
Condition: Intracranial Atherosclerosis
Intervention: Device: Wingspan Stent System
17 Recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
18 Recruiting Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Conditions: Stroke, Acute;   Cerebral Infarction
Interventions: Procedure: Endovascular Thrombectomy;   Device: Trevo Retriever;   Device: Solitaire™ FR Revascularization Device;   Device: Penumbra thrombectomy system;   Device: Covidien MindFrame Capture Revascularization Device
19 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
20 Recruiting A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
Condition: Acute Coronary Syndromes
Interventions: Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.